]>
IRCT20150204020951N4 IRCT 2018-01-21 Qazvin University of Medical Sciences Silymarine in control of diabetes type II DM Role of silymarine (livergol) in improving control indices of diabetes type II 2018-02-20 anticipated 60 Complete https://irct.ir/trial/28330 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple individual randomization using random numbers table, Blinding description: In the present study, patients who participate in the study will be blinded through administration of placebo. The researcher who will assess the out comes after complete of the study will be also blinded. N/A Diabetes Mellitus. The control group: will receive basic medical management included instructions for proper diet and avoiding sedentary lifestyle, administration of insulin and oral hypoglycemic if clinically indicated+ placebo. The study group: will receive basic medical management included instructions for proper diet and avoiding sedentary lifestyle, administration of insulin and oral hypoglycemic if clinically indicated+ silymarine.. Yes - There is a plan to make this available What will be shared: All data can be shared after removing the personal identifications. When: For six months after publication of results of the study To whom: Academic researchers in the field of medicine Conditions: For design of the future related study or meta-analysis Where to obtain: Via email of the corresponding author of the related article How to obtain: Within 30 days after the request and validation of the requesting person Comments:
public Bahram Mehrtash
Buali St.
Qazvin Iran (Islamic Republic of) 3413786165 +98 28 3333 2930 dr.houshmand@yahoo.com Qazvin University of Medical Sciences scientific Bahram Mehrtash
Buali St.
Qazvin Iran (Islamic Republic of) 3413786165 +98 28 3333 2930 dr.houshmand@yahoo.com Qazvin University of Medical Sciences Iran (Islamic Republic of) suffering from diabetes mellitus according to WHO criteria at least 1 year duration of the disease 40 years 70 years Both Presence of acute complications of DM (such as DKA) presence of vascular complications of DM presence of diabetic foot Other major renal, hepatic, and heart diseases E11 Type 2 diabetes mellitus Treatment - Drugs The control group: will receive basic medical management included instructions for proper diet and avoiding sedentary lifestyle, administration of insulin and oral hypoglycemic if clinically indicated+ placebo. The study group: will receive basic medical management included instructions for proper diet and avoiding sedentary lifestyle, administration of insulin and oral hypoglycemic if clinically indicated+ silymarine. Fasting Blood Sugar. Timepoint: Before the study; two and four months later. Method of measurement: As reported by laboratory. Lipid profile. Timepoint: Before the study; two and four months later. Method of measurement: As reported by laboratory. HbA1c. Timepoint: Before the study; four months later. Method of measurement: As reported by laboratory. Body Mass Index. Timepoint: Before the study; four months later. Method of measurement: By one of the researchers after measuring body weight and height. Qazvin University of Medical Sciences Approved 2017-07-26 Ethics committee of ًQazvin University of Medical Sciences Research Deputy; Faculty of Medicine; Qazvin University of Medical Sciences; Bahonar Blvd. Qazvin Qazvin Iran (Islamic Republic of)